FDA approves the first once-weekly basal insulin, cutting injections seven to one

The Food and Drug Administration approved Awiqli (insulin icodec-abae) on 26 March, licensing the first basal insulin designed to be injected once a week rather than once a day [s1]. The approval letter, signed electronically by Lisa B. Yanoff, M.D., Deputy Director of FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology, licenses the product under Novo Nordisk Inc.'s existing biologics license [s1]. Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [s1].

What was approved, and how it's dosed

Awiqli is a 700 units/mL insulin formulation supplied in a single-patient-use FlexTouch prefilled pen, available in three pen sizes holding 700, 1,050, or 2,100 total units [s1]. Basal insulin — the long-acting insulin that provides a steady baseline level throughout the day, as distinct from rapid-acting insulin taken around meals — has been injected daily since it first became a mainstay of diabetes treatment. Insulin icodec is engineered with a substantially longer half-life, which is what allows once-weekly dosing; the practical result FDA's approval formalizes is a reduction from seven injections a week to one [s1].

The product carries a defined dating period: 36 months from manufacture when refrigerated at 2–8°C, or up to 12 weeks at room temperature below 86°F for either an unopened or an in-use pen [s1] — storage flexibility relevant to patients who may not always have refrigeration available, such as when traveling.

What the approval was based on, and what's still outstanding

FDA's approval letter notes the agency did not refer the application to an outside advisory committee, stating there were no issues requiring that discussion [s1]. The license traces back to a biologics license application Novo Nordisk originally submitted in April 2023; FDA sent an action letter in July 2024, and the company's resubmission the following September constituted what the agency's letter calls "a complete response" that led to this approval [s1] — a regulatory history indicating the agency had prior concerns with the application that required an additional review cycle before approval.

Two conditions attach to the approval. Under the Pediatric Research Equity Act, FDA waived the requirement to study Awiqli in children under 10, reasoning that type 2 diabetes is uncommon enough in that age group that a dedicated study would be impractical [s1]. For adolescents aged 10 to under 18, the agency deferred rather than waived the requirement: Novo Nordisk must complete a pharmacokinetic study evaluating the drug in that age group, with a final report due by June 2026 [s1] — a deadline that falls within three months of this approval.

Why the delivery-frequency change matters beyond convenience

Basal insulin adherence is a documented problem in diabetes management: missed daily doses, whether from forgetfulness, needle aversion, or the simple burden of a lifelong daily regimen, contribute to the gap between insulin's demonstrated effectiveness in trials and its real-world performance. A weekly injection schedule doesn't change what insulin does biologically, but it does change how many opportunities a patient has to miss a dose — from 365 a year to 52. Whether that translates into meaningfully better real-world blood sugar control, as opposed to simply better trial-reported adherence, is a question that will depend on data FDA's approval doesn't yet include, since this is a new-to-market product without a post-approval real-world track record.

Awiqli also carries standard safety obligations common to biologic products: Novo Nordisk must submit adverse experience reports, distribution reports, and reports of any manufacturing deviations under FDA's standard biologics surveillance framework [s1], the same reporting infrastructure that applies to any newly licensed biologic regardless of how novel its dosing schedule is.

What to watch

The most immediate outstanding item is the adolescent pharmacokinetic study due in June — a relatively short window that will determine whether Awiqli's use can eventually extend to teenagers with type 2 diabetes, a population where the condition's rising incidence has made treatment options an active clinical concern. Beyond that, the approval sets up what is likely to become a competitive front in insulin therapy: this is the first FDA approval of a once-weekly basal insulin, and how it performs on the market — in adherence outcomes, in pricing, and in payer coverage decisions — will shape whether once-weekly dosing becomes the new standard against which other basal insulins are measured.

Sources

• BLA 761326/Original 2 — Awiqli (insulin icodec-abae) BLA Approval Letter — U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 26 March 2026